Share Price and Basic Stock Data
Last Updated: January 17, 2026, 7:32 am
| PEG Ratio | 3.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Neuland Laboratories Ltd, operating in the pharmaceuticals sector, reported a current price of ₹14,262 and a market capitalization of ₹18,289 Cr. The company’s revenue from operations demonstrated a robust growth trajectory, rising from ₹951 Cr in March 2022 to ₹1,191 Cr in March 2023, and further to ₹1,559 Cr in March 2024. However, the trailing twelve months (TTM) revenue stood at ₹1,533 Cr, indicating a slight decline compared to the previous fiscal year. Quarterly sales figures for September 2023 recorded ₹418 Cr, reflecting an increase from ₹363 Cr in June 2023, but a decrease from ₹514 Cr in September 2025. The operating profit margin (OPM) maintained a healthy level of 30%, although a dip was noted with the OPM falling to 12% in June 2025. This volatility in sales and profitability metrics highlights the dynamic nature of Neuland’s business environment and its ability to adapt to market conditions.
Profitability and Efficiency Metrics
Neuland Laboratories’ profitability metrics indicate a mixed performance. The net profit for the fiscal year ending March 2025 was ₹260 Cr, with an impressive net profit margin of 17.61%. The company recorded a return on equity (ROE) of 14.8% and a return on capital employed (ROCE) of 18.7%, showcasing effective utilization of equity and capital. The interest coverage ratio (ICR) stood at an impressive 41.43x, reflecting strong earnings relative to interest obligations. However, the price-to-earnings (P/E) ratio of 93.4 suggests that the stock may be overvalued compared to industry standards. The cash conversion cycle (CCC) of 160 days indicates the time taken to convert investments in inventory and other resources into cash flows, which could be improved. Overall, while profitability remains strong, efficiency metrics warrant attention for further enhancements.
Balance Sheet Strength and Financial Ratios
Neuland Laboratories’ balance sheet reflects a solid foundation with total assets amounting to ₹2,534 Cr and total liabilities at ₹2,180 Cr, resulting in a debt-to-equity ratio of 0.08. This low leverage indicates a conservative capital structure and financial stability. The company’s reserves increased to ₹1,607 Cr, up from ₹1,512 Cr in March 2025, highlighting a strong retained earnings position. With borrowings reported at ₹265 Cr, the company maintains a manageable debt level. The current ratio of 2.45 and quick ratio of 1.62 suggest robust liquidity, allowing the company to meet its short-term obligations. However, the price-to-book value (P/BV) ratio of 10.22x indicates that the stock is trading at a significant premium, which may raise concerns for value investors. Overall, Neuland’s balance sheet is strong, yet it faces challenges regarding valuation and market perceptions.
Shareholding Pattern and Investor Confidence
Neuland Laboratories’ shareholding pattern reveals a diversified ownership structure, with promoters holding 32.64% of the company, while foreign institutional investors (FIIs) accounted for 20.60%. Domestic institutional investors (DIIs) held 13.55%, and the public constituted 32.80%. The number of shareholders increased to 44,393, indicating growing investor interest. The reduction in promoter holding from 36.14% in December 2022 to the current level may signal a gradual dilution of control, which could concern some investors. Conversely, the increasing stake of FIIs, which rose from 17.70% in December 2022 to 20.60%, reflects enhanced confidence in Neuland’s growth potential. This diverse ownership structure can be interpreted as a healthy sign of market interest, although the fluctuating promoter stake may raise questions about long-term governance.
Outlook, Risks, and Final Insight
The outlook for Neuland Laboratories appears promising, driven by strong sales growth and significant profitability metrics. However, challenges remain, particularly regarding market valuation and operational efficiency. The high P/E ratio suggests that the stock may face downward pressure if earnings do not meet investor expectations. Additionally, fluctuations in quarterly sales and OPM could pose risks to sustained profitability. On the upside, the company’s strong balance sheet and increasing institutional investor interest provide a solid foundation for future growth. In a scenario where operational efficiencies improve and sales stabilize at higher levels, Neuland could enhance its profitability and shareholder value. Conversely, if market conditions worsen or if costs rise significantly, the company may struggle to maintain its current profit margins. Overall, while Neuland Laboratories has several strengths, careful monitoring of operational metrics and market sentiment will be essential for long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 205/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,910 Cr. | 356 | 479/192 | 81.0 | 24.3 | 0.19 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 45.9 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,986.51 Cr | 1,115.90 | 52.25 | 202.18 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 294 | 269 | 407 | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 | 514 |
| Expenses | 224 | 215 | 287 | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 | 359 |
| Operating Profit | 69 | 54 | 120 | 97 | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 | 156 |
| OPM % | 24% | 20% | 29% | 27% | 33% | 31% | 28% | 28% | 20% | 22% | 16% | 12% | 30% |
| Other Income | 0 | 1 | 8 | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 | 2 |
| Interest | 3 | 3 | 4 | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 13 | 13 | 13 | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 | 23 |
| Profit before tax | 53 | 39 | 110 | 83 | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 | 129 |
| Tax % | 28% | 22% | 23% | 26% | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% |
| Net Profit | 38 | 31 | 85 | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 | 97 |
| EPS in Rs | 29.98 | 23.81 | 65.89 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.68 | 10.83 | 75.49 |
Last Updated: December 29, 2025, 8:07 pm
Below is a detailed analysis of the quarterly data for Neuland Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 514.00 Cr.. The value appears strong and on an upward trend. It has increased from 293.00 Cr. (Jun 2025) to 514.00 Cr., marking an increase of 221.00 Cr..
- For Expenses, as of Sep 2025, the value is 359.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 258.00 Cr. (Jun 2025) to 359.00 Cr., marking an increase of 101.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Jun 2025) to 156.00 Cr., marking an increase of 122.00 Cr..
- For OPM %, as of Sep 2025, the value is 30.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Jun 2025) to 30.00%, marking an increase of 18.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 6.00 Cr..
- For Interest, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 5.00 Cr..
- For Depreciation, as of Sep 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.00 Cr. (Jun 2025) to 23.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 129.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Jun 2025) to 129.00 Cr., marking an increase of 111.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 21.00% (Jun 2025) to 25.00%, marking an increase of 4.00%.
- For Net Profit, as of Sep 2025, the value is 97.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Jun 2025) to 97.00 Cr., marking an increase of 83.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 75.49. The value appears strong and on an upward trend. It has increased from 10.83 (Jun 2025) to 75.49, marking an increase of 64.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:54 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 1,533 |
| Expenses | 395 | 402 | 430 | 472 | 477 | 608 | 661 | 790 | 807 | 918 | 1,096 | 1,146 | 1,206 |
| Operating Profit | 71 | 67 | 80 | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 463 | 331 | 328 |
| OPM % | 15% | 14% | 16% | 18% | 10% | 9% | 13% | 16% | 15% | 23% | 30% | 22% | 21% |
| Other Income | 3 | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 12 | 90 | 77 |
| Interest | 25 | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 14 | 13 | 14 | 8 | 15 |
| Depreciation | 15 | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 | 76 |
| Profit before tax | 35 | 25 | 42 | 67 | 14 | 20 | 53 | 105 | 82 | 216 | 401 | 346 | 314 |
| Tax % | 23% | 36% | 36% | 30% | 13% | 19% | 69% | 23% | 22% | 24% | 25% | 25% | |
| Net Profit | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 240 |
| EPS in Rs | 30.12 | 17.96 | 30.75 | 52.74 | 13.57 | 12.81 | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 187.18 |
| Dividend Payout % | 9% | 8% | 7% | 0% | 0% | 0% | 16% | 8% | 10% | 8% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -40.74% | 68.75% | 74.07% | -74.47% | 33.33% | 0.00% | 406.25% | -20.99% | 156.25% | 82.93% | -13.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 109.49% | 5.32% | -148.54% | 107.80% | -33.33% | 406.25% | -427.24% | 177.24% | -73.32% | -96.26% |
Neuland Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 14% |
| 3 Years: | 16% |
| TTM: | -19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 67% |
| 3 Years: | 47% |
| TTM: | -59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 71% |
| 3 Years: | 130% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 16% |
| 3 Years: | 19% |
| Last Year: | 15% |
Last Updated: September 5, 2025, 11:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:43 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 116 | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 | 1,512 | 1,607 |
| Borrowings | 190 | 188 | 182 | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 95 | 157 | 265 |
| Other Liabilities | 169 | 162 | 155 | 148 | 194 | 200 | 257 | 356 | 302 | 457 | 454 | 498 | 649 |
| Total Liabilities | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,534 |
| Fixed Assets | 131 | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 | 955 | 1,076 |
| CWIP | 35 | 41 | 40 | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 48 | 140 |
| Investments | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 | 114 |
| Other Assets | 311 | 340 | 337 | 393 | 463 | 476 | 547 | 585 | 592 | 781 | 962 | 1,068 | 1,204 |
| Total Assets | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,534 |
Below is a detailed analysis of the balance sheet data for Neuland Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,607.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,512.00 Cr. (Mar 2025) to 1,607.00 Cr., marking an increase of 95.00 Cr..
- For Borrowings, as of Sep 2025, the value is 265.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 157.00 Cr. (Mar 2025) to 265.00 Cr., marking an increase of 108.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 649.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 498.00 Cr. (Mar 2025) to 649.00 Cr., marking an increase of 151.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,534.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,180.00 Cr. (Mar 2025) to 2,534.00 Cr., marking an increase of 354.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,076.00 Cr.. The value appears strong and on an upward trend. It has increased from 955.00 Cr. (Mar 2025) to 1,076.00 Cr., marking an increase of 121.00 Cr..
- For CWIP, as of Sep 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 48.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 92.00 Cr..
- For Investments, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 109.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,204.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,068.00 Cr. (Mar 2025) to 1,204.00 Cr., marking an increase of 136.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,534.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,180.00 Cr. (Mar 2025) to 2,534.00 Cr., marking an increase of 354.00 Cr..
Notably, the Reserves (1,607.00 Cr.) exceed the Borrowings (265.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -119.00 | -121.00 | -102.00 | -86.00 | -268.00 | -173.00 | -162.00 | -35.00 | -97.00 | 145.00 | 368.00 | 174.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 100 | 85 | 114 | 134 | 90 | 91 | 85 | 90 | 111 | 87 | 78 |
| Inventory Days | 138 | 170 | 182 | 186 | 266 | 191 | 209 | 205 | 227 | 211 | 220 | 238 |
| Days Payable | 139 | 167 | 121 | 118 | 189 | 118 | 110 | 126 | 100 | 129 | 121 | 156 |
| Cash Conversion Cycle | 92 | 103 | 147 | 182 | 211 | 162 | 190 | 164 | 216 | 193 | 187 | 160 |
| Working Capital Days | -21 | 11 | 26 | 44 | 38 | 44 | 49 | 60 | 74 | 81 | 88 | 76 |
| ROCE % | 19% | 16% | 18% | 16% | 4% | 4% | 8% | 11% | 10% | 21% | 33% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Flexicap Fund | 270,843 | 2.33 | 468.23 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 161,718 | 1.73 | 279.58 | 166,718 | 2025-12-14 08:14:20 | -3% |
| Mahindra Manulife Small Cap Fund | 64,583 | 2.64 | 111.65 | N/A | N/A | N/A |
| Mahindra Manulife Multi Cap Fund | 55,227 | 1.56 | 95.48 | 36,000 | 2025-12-13 07:59:26 | 53.41% |
| Bandhan Small Cap Fund | 54,813 | 0.52 | 94.76 | 59,213 | 2025-12-15 06:52:35 | -7.43% |
| Sundaram Small Cap Fund | 44,855 | 2.25 | 77.55 | N/A | N/A | N/A |
| Mahindra Manulife Large & Mid Cap Fund | 27,800 | 1.72 | 48.06 | N/A | N/A | N/A |
| ITI Small Cap Fund | 25,861 | 1.59 | 44.71 | N/A | N/A | N/A |
| PGIM India Flexi Cap Fund | 25,605 | 0.69 | 44.27 | N/A | N/A | N/A |
| HSBC Focused Fund | 25,000 | 2.51 | 43.22 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
| Diluted EPS (Rs.) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
| Cash EPS (Rs.) | 252.44 | 278.89 | 167.66 | 87.49 | 93.26 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1181.32 | 993.65 | 769.94 | 650.88 | 608.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1181.97 | 994.31 | 770.59 | 651.52 | 609.63 |
| Revenue From Operations / Share (Rs.) | 1144.79 | 1208.16 | 923.37 | 737.24 | 726.26 |
| PBDIT / Share (Rs.) | 266.48 | 368.31 | 218.28 | 112.16 | 126.29 |
| PBIT / Share (Rs.) | 215.67 | 322.03 | 177.37 | 74.15 | 95.52 |
| PBT / Share (Rs.) | 268.46 | 311.18 | 167.24 | 63.69 | 81.65 |
| Net Profit / Share (Rs.) | 201.63 | 232.61 | 126.75 | 49.47 | 62.50 |
| NP After MI And SOA / Share (Rs.) | 201.63 | 232.61 | 126.75 | 49.47 | 62.50 |
| PBDIT Margin (%) | 23.27 | 30.48 | 23.63 | 15.21 | 17.38 |
| PBIT Margin (%) | 18.83 | 26.65 | 19.20 | 10.05 | 13.15 |
| PBT Margin (%) | 23.45 | 25.75 | 18.11 | 8.63 | 11.24 |
| Net Profit Margin (%) | 17.61 | 19.25 | 13.72 | 6.71 | 8.60 |
| NP After MI And SOA Margin (%) | 17.61 | 19.25 | 13.72 | 6.71 | 8.60 |
| Return on Networth / Equity (%) | 17.06 | 23.40 | 16.46 | 7.60 | 10.26 |
| Return on Capital Employeed (%) | 16.23 | 29.57 | 20.05 | 9.37 | 12.88 |
| Return On Assets (%) | 11.93 | 16.37 | 10.35 | 4.61 | 6.08 |
| Long Term Debt / Equity (X) | 0.05 | 0.03 | 0.07 | 0.12 | 0.11 |
| Total Debt / Equity (X) | 0.08 | 0.06 | 0.12 | 0.27 | 0.18 |
| Asset Turnover Ratio (%) | 0.73 | 0.91 | 0.80 | 0.70 | 0.73 |
| Current Ratio (X) | 2.45 | 2.15 | 1.73 | 1.60 | 1.49 |
| Quick Ratio (X) | 1.62 | 1.33 | 1.10 | 0.87 | 0.81 |
| Inventory Turnover Ratio (X) | 4.01 | 2.01 | 1.79 | 1.71 | 1.88 |
| Dividend Payout Ratio (NP) (%) | 6.90 | 4.27 | 3.92 | 6.03 | 3.18 |
| Dividend Payout Ratio (CP) (%) | 5.51 | 3.56 | 2.96 | 3.41 | 2.13 |
| Earning Retention Ratio (%) | 93.10 | 95.73 | 96.08 | 93.97 | 96.82 |
| Cash Earning Retention Ratio (%) | 94.49 | 96.44 | 97.04 | 96.59 | 97.87 |
| Interest Coverage Ratio (X) | 41.43 | 33.94 | 21.55 | 10.72 | 9.10 |
| Interest Coverage Ratio (Post Tax) (X) | 23.14 | 22.44 | 13.51 | 5.73 | 5.50 |
| Enterprise Value (Cr.) | 15457.06 | 8068.90 | 2383.79 | 1534.95 | 2819.28 |
| EV / Net Operating Revenue (X) | 10.47 | 5.18 | 2.00 | 1.61 | 3.01 |
| EV / EBITDA (X) | 44.96 | 16.98 | 8.47 | 10.61 | 17.31 |
| MarketCap / Net Operating Revenue (X) | 10.55 | 5.20 | 1.95 | 1.39 | 2.87 |
| Retention Ratios (%) | 93.09 | 95.72 | 96.07 | 93.96 | 96.81 |
| Price / BV (X) | 10.22 | 6.32 | 2.34 | 1.58 | 3.43 |
| Price / Net Operating Revenue (X) | 10.55 | 5.20 | 1.95 | 1.39 | 2.87 |
| EarningsYield | 0.01 | 0.03 | 0.07 | 0.04 | 0.02 |
After reviewing the key financial ratios for Neuland Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 202.74. This value is within the healthy range. It has decreased from 233.89 (Mar 24) to 202.74, marking a decrease of 31.15.
- For Diluted EPS (Rs.), as of Mar 25, the value is 202.74. This value is within the healthy range. It has decreased from 233.89 (Mar 24) to 202.74, marking a decrease of 31.15.
- For Cash EPS (Rs.), as of Mar 25, the value is 252.44. This value is within the healthy range. It has decreased from 278.89 (Mar 24) to 252.44, marking a decrease of 26.45.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,181.32. It has increased from 993.65 (Mar 24) to 1,181.32, marking an increase of 187.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,181.97. It has increased from 994.31 (Mar 24) to 1,181.97, marking an increase of 187.66.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,144.79. It has decreased from 1,208.16 (Mar 24) to 1,144.79, marking a decrease of 63.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 266.48. This value is within the healthy range. It has decreased from 368.31 (Mar 24) to 266.48, marking a decrease of 101.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 215.67. This value is within the healthy range. It has decreased from 322.03 (Mar 24) to 215.67, marking a decrease of 106.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 268.46. This value is within the healthy range. It has decreased from 311.18 (Mar 24) to 268.46, marking a decrease of 42.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 201.63. This value is within the healthy range. It has decreased from 232.61 (Mar 24) to 201.63, marking a decrease of 30.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 201.63. This value is within the healthy range. It has decreased from 232.61 (Mar 24) to 201.63, marking a decrease of 30.98.
- For PBDIT Margin (%), as of Mar 25, the value is 23.27. This value is within the healthy range. It has decreased from 30.48 (Mar 24) to 23.27, marking a decrease of 7.21.
- For PBIT Margin (%), as of Mar 25, the value is 18.83. This value is within the healthy range. It has decreased from 26.65 (Mar 24) to 18.83, marking a decrease of 7.82.
- For PBT Margin (%), as of Mar 25, the value is 23.45. This value is within the healthy range. It has decreased from 25.75 (Mar 24) to 23.45, marking a decrease of 2.30.
- For Net Profit Margin (%), as of Mar 25, the value is 17.61. This value exceeds the healthy maximum of 10. It has decreased from 19.25 (Mar 24) to 17.61, marking a decrease of 1.64.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.61. This value is within the healthy range. It has decreased from 19.25 (Mar 24) to 17.61, marking a decrease of 1.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.06. This value is within the healthy range. It has decreased from 23.40 (Mar 24) to 17.06, marking a decrease of 6.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.23. This value is within the healthy range. It has decreased from 29.57 (Mar 24) to 16.23, marking a decrease of 13.34.
- For Return On Assets (%), as of Mar 25, the value is 11.93. This value is within the healthy range. It has decreased from 16.37 (Mar 24) to 11.93, marking a decrease of 4.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.08. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.08, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.91 (Mar 24) to 0.73, marking a decrease of 0.18.
- For Current Ratio (X), as of Mar 25, the value is 2.45. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.45, marking an increase of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 1.62. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.62, marking an increase of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.01. This value is within the healthy range. It has increased from 2.01 (Mar 24) to 4.01, marking an increase of 2.00.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.90. This value is below the healthy minimum of 20. It has increased from 4.27 (Mar 24) to 6.90, marking an increase of 2.63.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.51. This value is below the healthy minimum of 20. It has increased from 3.56 (Mar 24) to 5.51, marking an increase of 1.95.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.10. This value exceeds the healthy maximum of 70. It has decreased from 95.73 (Mar 24) to 93.10, marking a decrease of 2.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.49. This value exceeds the healthy maximum of 70. It has decreased from 96.44 (Mar 24) to 94.49, marking a decrease of 1.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 41.43. This value is within the healthy range. It has increased from 33.94 (Mar 24) to 41.43, marking an increase of 7.49.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.14. This value is within the healthy range. It has increased from 22.44 (Mar 24) to 23.14, marking an increase of 0.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,457.06. It has increased from 8,068.90 (Mar 24) to 15,457.06, marking an increase of 7,388.16.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 10.47. This value exceeds the healthy maximum of 3. It has increased from 5.18 (Mar 24) to 10.47, marking an increase of 5.29.
- For EV / EBITDA (X), as of Mar 25, the value is 44.96. This value exceeds the healthy maximum of 15. It has increased from 16.98 (Mar 24) to 44.96, marking an increase of 27.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.55. This value exceeds the healthy maximum of 3. It has increased from 5.20 (Mar 24) to 10.55, marking an increase of 5.35.
- For Retention Ratios (%), as of Mar 25, the value is 93.09. This value exceeds the healthy maximum of 70. It has decreased from 95.72 (Mar 24) to 93.09, marking a decrease of 2.63.
- For Price / BV (X), as of Mar 25, the value is 10.22. This value exceeds the healthy maximum of 3. It has increased from 6.32 (Mar 24) to 10.22, marking an increase of 3.90.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.55. This value exceeds the healthy maximum of 3. It has increased from 5.20 (Mar 24) to 10.55, marking an increase of 5.35.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neuland Laboratories Ltd:
- Net Profit Margin: 17.61%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.23% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.06% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.62
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 92.3 (Industry average Stock P/E: 52.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.08
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.61%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 11th Floor (5th Office Level), Phoenix IVY Building, Hyderabad Telangana 500033 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Davuluri Rama Mohan Rao | Executive Chairman |
| Mr. Davuluri Sucheth Rao | Vice Chairman & CEO |
| Mr. Davuluri Saharsh Rao | Vice Chairman & Mng.Director |
| Dr. Christopher M Cimarusti | Non Executive Director |
| Mr. Homi Rustum Khusrokhan | Ind. Non-Executive Director |
| Mr. Prasad Raghava Menon | Ind. Non-Executive Director |
| Mr. Sugata Sircar | Ind. Non-Executive Director |
| Ms. Pallavi Joshi Bakhru | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Neuland Laboratories Ltd?
Neuland Laboratories Ltd's intrinsic value (as of 17 January 2026) is ₹18007.70 which is 27.83% higher the current market price of ₹14,087.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹18,073 Cr. market cap, FY2025-2026 high/low of ₹19,748/10,060, reserves of ₹1,607 Cr, and liabilities of ₹2,534 Cr.
What is the Market Cap of Neuland Laboratories Ltd?
The Market Cap of Neuland Laboratories Ltd is 18,073 Cr..
What is the current Stock Price of Neuland Laboratories Ltd as on 17 January 2026?
The current stock price of Neuland Laboratories Ltd as on 17 January 2026 is ₹14,087.
What is the High / Low of Neuland Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Neuland Laboratories Ltd stocks is ₹19,748/10,060.
What is the Stock P/E of Neuland Laboratories Ltd?
The Stock P/E of Neuland Laboratories Ltd is 92.3.
What is the Book Value of Neuland Laboratories Ltd?
The Book Value of Neuland Laboratories Ltd is 1,263.
What is the Dividend Yield of Neuland Laboratories Ltd?
The Dividend Yield of Neuland Laboratories Ltd is 0.09 %.
What is the ROCE of Neuland Laboratories Ltd?
The ROCE of Neuland Laboratories Ltd is 18.7 %.
What is the ROE of Neuland Laboratories Ltd?
The ROE of Neuland Laboratories Ltd is 14.8 %.
What is the Face Value of Neuland Laboratories Ltd?
The Face Value of Neuland Laboratories Ltd is 10.0.